Sensor Device as a defense against COVID -19 Gastrointestinal and Respiratory System
Intestinal epithelial cells maintain gut homeostasis and the prevention of intestinal inflammation.
Our sensor device will target cell signaling mediators in the modulation of immune responses such as inflammation.
The device will detect epithelial cells which line the inner surface of the small and large intestine and monitor inflammatory responses or cell signaling mediators.
Interferon also seems to regulate ACE2 levels and are susceptible to SARS-CoV-2 infection. The device will also detect interferon signaling.
The device will detect and monitor ACE2 cells in the lungs and GI tract. If there is an increase in inflammatory responses, the sensor device will detect cell signaling mediators and send out an alert via devices in real time.
Researchers have found that COVID-19 attacks the respiratory system as well as the Gastrointestinal tract. ACE2 is present in the epithelium and is found in the nose, mouth and lungs. ACE2 is a vital element that is critical to regulating processes such as inflammation, blood pressure and wound healing. COVID-19 can increase inflammation by gaining access by binding to ACE2 using its spike-like protein on its surface. When COVID-19 binds to ACE2, it prevents ACE2 from performing its normal functions, increasing inflammation, increasing damage to blood vessel linings and various types of tissue injury.
ACE2 is also present in the gastrointestinal tract. COVID-19 infects cells that line the small and large intestine called gut enterocytes. The enterocytes are found in the inner mucus layer and play an important role in the barrier against enteric pathogens. Enteric pathogens infiltrate or evade secreted or cellular barriers and alter gut ecosystems, invading the host and leads to intestinal disorders and diseases such as Crohns, Colitis, and Inflammatory Bowel Disease. These diseases involve the chronic inflammation of all or part of the digestive tract.
Sensor Detection of Mucosal Pathogens such as COVID-19
We must strive to develop and innovate new methods to combat this virus. We should not wait for an effective vaccine againist COVID-19 that provides 100% protection while thousands of people die in the United States and globally. It is imperative that we focus on therapeutics and therapies that will help improve patient outcomes and their quality of life.
Learn more about the EXCELOLIFE COVID-19 INITIATIVE
